4 years of revenue, earnings, cash-flow and balance-sheet history from public filings.
Foghorn Therapeutics Inc. (FHTX) operates in the Biotechnology industry and is headquartered in Watertown, United States with about 106 employees. Its market capitalization is roughly $350 million. In the fiscal year ended 2025-12-31, FHTX reported $31M in revenue and ($74M) in net income.
Foghorn Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of medicines targeting genetically determined dependencies within the chromatin regulatory system in the United States.
Interactive charts & full statements → Open the FHTX valuation workbench →
| Income statement | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Total Revenue | $31M | $23M | $34M | $19M | — |
| Operating Income (EBIT) | ($82M) | ($100M) | ($108M) | ($117M) | — |
| Net Income | ($74M) | ($87M) | ($98M) | ($109M) | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Quarterly income statement | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 |
|---|---|---|---|---|---|---|
| Total Revenue | $3M | $9M | $8M | $8M | $6M | — |
| Operating Income (EBIT) | ($22M) | ($20M) | ($18M) | ($21M) | ($23M) | — |
| Net Income | ($20M) | ($22M) | ($16M) | ($18M) | ($19M) | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Balance sheet | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Total Assets | $198M | $284M | $286M | $405M | — |
| Total Liabilities | $307M | $330M | $363M | $405M | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive FHTX viewer.
About TickerBase · Data methodology & sources